Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
about
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsProtein kinases and phosphatases in the control of cell fatemTOR inhibitors in advanced renal cell carcinomaThe mTOR signalling pathway in human cancerNext-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyState of the science: an update on renal cell carcinomamTOR signaling in growth control and diseaseThe VHL tumor suppressor: master regulator of HIFTargeting the mTOR signaling network for cancer therapyHypoxia-Inducible Factors (HIFs) and Phosphorylation: Impact on Stability, Localization, and TransactivityMonitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studiesClinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaToward rapamycin analog (rapalog)-based precision cancer therapyTherapeutic challenges in renal cell carcinomaCancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasisAMPK: opposing the metabolic changes in both tumour cells and inflammatory cells?HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progressionCIViC databaseExploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologiesEverolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapymTOR and cancer therapyAntitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinomaThe tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptakeThe histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibitionTargeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitorsActivation of a metabolic gene regulatory network downstream of mTOR complex 1Targeting the phosphoinositide 3-kinase pathway in cancerDefining the role of hypoxia-inducible factor 1 in cancer biology and therapeuticsThe impact of O2 availability on human cancerEnergy sensing pathways: Bridging type 2 diabetes and colorectal cancer?Molecular imaging agents: impact on diagnosis and therapeutics in oncologyAkt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.Hypoxia-specific ultrasensitive detection of tumours and cancer cells in vivo.Role of the ubiquitin proteasome system in renal cell carcinoma.Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth.Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.Evaluation of everolimus in renal cell cancer.Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
P2860
Q21183974-CF5AF80C-330E-4F3B-AD7A-272CD9CC8AB9Q24604987-8B7507AB-F577-4BD7-AC6D-FD40D8A69B8DQ24612127-59B2FF32-B6F4-4DFF-879C-637C80966772Q24627306-0CBAD111-E840-4ADE-B06E-0ECF56B2602AQ24628724-A01AF351-2FF4-45A0-93BA-288C3DC797E8Q24630685-1BABEFC7-25F1-49D6-8FD9-5228EE9915B9Q24634174-3C980DD1-FA3A-4F5F-857B-9CA5E7BE036FQ24634592-082DE95F-724F-4BEF-826B-695D192CDBB4Q24658334-255BBF42-8095-4720-BF54-BAD4213AFE5AQ26768230-868ACC18-1CB2-4170-B26D-442A8C0DF16FQ26778463-3DD22DE2-9FF0-4012-838C-672BC937597BQ26783514-A8916ED9-B32D-4A84-9C92-850506660121Q26795606-794F27FA-346D-4F11-AA14-C0A6CED539C1Q26796702-1029642E-20FC-4C00-96D2-792639F42EB6Q26866144-763862AF-84E7-4079-B6BA-2CBEC1D145C4Q26866512-A6E8F31A-B658-408D-85E2-37FADAA66C7EQ27025886-54185993-B61F-4C08-A284-96320F612B0DQ27612411-31E87C4D-0D53-4B89-8870-87FE6C786869Q27701444-AB5F5F5F-AB76-4177-8D38-DD3B38AF51A8Q28079861-587ACE7F-14A6-4D44-ABB6-4C9E83E6ADCBQ28268516-4468B99A-302B-4A03-9DEC-8467ECD7F5C7Q28472048-F307861C-E8A3-4B02-A7C8-03ECA728DAE5Q28479196-548EC6E2-B547-4037-A444-1D9CE1D1ABE3Q28512637-AB86F6AB-61F3-42D7-ABAC-AF89315EFE23Q28542639-615A6D10-E009-45C9-A57A-01A7A0728946Q28822228-FAD1E7B9-8A3D-49B0-97BF-6A0AB5E1C6F8Q29615179-5057915A-6B5B-476C-B9A1-61297D37989FQ29615809-324591A2-44DC-46DE-9FFE-D7418B820E7CQ29615944-62EA251B-FC72-4ACF-A10D-746DC8E69F44Q29619884-9B04DDA3-5C73-4095-BC25-1380F565F9C5Q30234587-5FF4A583-D77E-4DDA-86CE-1413EE4AE113Q30433423-0C103477-7909-4C56-9EE8-9C18509110E8Q30440717-5A6E4F45-6B13-4346-8B4E-EDF348860D6EQ30882619-4EE43108-CB7A-49AD-B59D-EBACACB45276Q33307879-7417945D-1E22-49B2-B23E-E1EF1675B1E2Q33385608-22868585-82D0-44FB-AC85-CFD9FCA1B892Q33401986-EA683BB1-1375-43EA-A67F-031FD593159AQ33407015-6E9A7702-169E-42B0-BC0F-47F16EEDE858Q33423777-D4E02FED-7E15-437A-9D31-7AE6F7F911C2Q33493174-C32247EF-D455-4A63-B08A-AA83D50A9C4D
P2860
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
@ast
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
@en
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
@nl
type
label
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
@ast
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
@en
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
@nl
prefLabel
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
@ast
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
@en
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
@nl
P2093
P2860
P3181
P356
P1433
P1476
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.
@en
P2093
Barbara Fueger
Charles L Sawyers
Chris Tran
Derek S Welsbie
Emily Chan
George V Thomas
Ingo K Mellinghoff
Johannes Czernin
P2860
P2888
P3181
P356
10.1038/NM1337
P407
P577
2006-01-01T00:00:00Z
P6179
1015724778